Breaking Finance News

Flex Pharma Inc (NASDAQ:FLKS) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.

Having a price of $3.37, Flex Pharma Inc (NASDAQ:FLKS) traded 0.00% even on the day. With the last close down -29.78% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.01% over the same period. FLKS has recorded a 50-day average of $3.81 and a two hundred day average of $4.93. Trade Volume was down over the average, with 41,184 shares of FLKS changing hands under the typical 65,610

Zacks Investment Research has downgraded Flex Pharma Inc (NASDAQ:FLKS) to Sell in a statement released on 5/23/2017.

Recent Performance Chart

Flex Pharma Inc (NASDAQ:FLKS)

Flex Pharma Inc has with a one year low of $3.01 and a one year high of $13.97 and has a market capitalization of $0.

A total of 6 analysts have released a report on Flex Pharma Inc. One analyst rating the company a strong buy, five analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $27.00.

General Company Details For Flex Pharma Inc (NASDAQ:FLKS)

Flex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company's product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company's lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *